A recent study exploring cancer diagnosis complexities suggests that our reliance on biomarkers, like mismatch repair deficiency, may not be as reliable as thought, prompting a need for more personalised treatment strategies. Parallel advancements in cancer treatment include T-cell therapy enhancements aimed at combating solid tumors, and the use of modified oncolytic viruses for tumor reduction and immune system fortification.
There is, however, a concerning gap in genetic testing among cancer patients that needs to be addressed, as it holds valuable data for treatment strategies and understanding familial cancer risks. In brighter news, the ComboMATCH initiative is identifying beneficial drug combinations through phase 2 trials, which could greatly change cancer therapy. Finally, mRNA vaccines demonstrate potential in mouse models, indicating a positive shift in HPV-related cancer combat and spotlighting the importance of continued research in this field.
Full article here: https://medium.com/@lawsuithelpdesk/unmasking-the-limitations-of-cancer-biomarkers-a-critical-look-at-mismatch-repair-deficiency-18de32a467af
